CClinicalTrials.gg
Status unknownNCT04679636Updated Mar 23, 2023

Effects of HRV Biofeedback on Autonomic Function and Nicotine Withdrawal Symptoms and Dependence in Smoking Cessation Adults

An interventional study of heart rate variability biofeedback in Heart Rate Variability, Biofeedback, Nicotine Dependence, Nicotine Withdrawal, Anxiety, Depression, Insomnia, sponsored by National Defense Medical Center, Taiwan. Status unknown at 1 site in Taiwan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2023-03-23.

Sponsored by National Defense Medical Center, Taiwan · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2023), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Study summary

This study is a randomized controlled trial. It is estimated that 80 quitters will be recruited, and they will be randomly included in the experimental group and 40 in the control group. The experimental group will be involved in heart rate variability biological feedback training for eight weeks, and the control group will receive conventional treatment. Use the scale to assess the symptoms of nicotine withdrawal-anxiety, depression and insomnia, as well as the degree of nicotine dependence before and after the intervention; the autonomic nervous function of the participants was measured by heart rhythm variation before and after the intervention; in addition, the cessation of smoking was tracked by telephone once a month for six Months. Discuss interventional biological feedback training and evaluate its effectiveness in improving heart rate variability, which represents autonomic nervous function, and alleviating nicotine withdrawal anxiety, insomnia, and depression symptoms, as well as nicotine dependence.

Read the detailed description

Smoking cessation has been one of the priorities in public health for many years, because the severity of the disease and the social and economic losses caused by smoking cannot be ignored. Among them, nicotine dependence is one of the important issues in quitting smoking. Nicotine withdrawal symptoms often make the quitters' actions fail, especially anxiety, insomnia, and depression, which further affect the lives of quitters. If an intervention can be provided to improve the nicotine withdrawal symptoms of quitters and reduce nicotine dependence, it should be able to improve the effectiveness of smoking cessation.This study is a randomized controlled trial to facilitate sampling. It is expected that 80 quitters will be recruited at the smoking cessation clinic of the medical center through the referral of the attending physician, and 40 will be randomly included in the experimental group and the control group. The experimental group will receive biofeedback training for heart rate variability for eight weeks, while the control group will receive conventional treatment. Use the scale to assess nicotine withdrawal symptoms before and after intervention-the degree of anxiety (Beck Anxiety Inventory), depression (Beck Depression Inventory) and insomnia (Pittsburgh Sleep Quality Index), And the degree of nicotine dependence (Nicotine Dependence Scale; Fagerstrom Test for Nicotine Dependence); the autonomic nerve function of the participants was measured by heart rhythm variability before and after the intervention; in addition, the cessation of smoking was tracked by telephone once a month for six months. This study is mainly to explore interventional biological feedback training to evaluate its effectiveness in improving the representative autonomic nervous function-heart rate variability and alleviating nicotine withdrawal anxiety, insomnia and depression symptoms and nicotine dependence.

02

Conditions studied

  • Heart Rate Variability, Biofeedback, Nicotine Dependence, Nicotine Withdrawal, Anxiety, Depression, Insomnia
03

In context

Tobacco Use Disorder

968 studies on the registry are indexed under Tobacco Use Disorder; 126 are open to participants now.

This study's planned enrollment of 80 is below the median of 89 across 851 interventional studies indexed under Tobacco Use Disorder.

Browse Tobacco Use Disorder studies →

Lead sponsor

National Defense Medical Center, Taiwan is the lead sponsor of 63 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Willing to quit smoking
  2. Clear consciousness
  3. Able to communicate in Mandarin or Taiwanese

Exclusion criteria

Exclusion Criteria:

  1. Diagnosed with asthma or chronic obstructive pulmonary disease
  2. Diagnosed with nervous system
  3. Diagnosis of mental illness
  4. Arrhythmia, use of cardiac pacemakers, and atrioventricular conduction disorders
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Experimental group

    receive biofeedback training for heart rate variability for eight weeks

    Behavioral: heart rate variability biofeedback

  • No intervention
    Control group

    receive conventional treatment

Interventions

  • Behavioralheart rate variability biofeedback

    receive biofeedback training for heart rate variability for eight weeks

06

What researchers measure

Primary outcomes

  1. autonomic nerve function

    heart rate variability index

    Time frame: baseline

  2. autonomic nerve function

    heart rate variability index

    Time frame: 1 month

  3. autonomic nerve function

    heart rate variability index

    Time frame: 2 month

  4. autonomic nerve function

    heart rate variability index

    Time frame: 6 month

Secondary outcomes

  1. symptom distress(Anxiety)

    Beck Anxiety Inventory

    Time frame: baseline

  2. symptom distress(Anxiety)

    Beck Anxiety Inventory

    Time frame: 1 month

  3. symptom distress(Anxiety)

    Beck Anxiety Inventory

    Time frame: 2 month

  4. symptom distress(Anxiety)

    Beck Anxiety Inventory

    Time frame: 6 month

  5. symptom distress(Depression)

    Beck Depression Inventory-II

    Time frame: baseline

  6. symptom distress(Depression)

    Beck Depression Inventory-II

    Time frame: 1 month

  7. symptom distress(Depression)

    Beck Depression Inventory-II

    Time frame: 2 month

  8. symptom distress(Depression)

    Beck Depression Inventory-II

    Time frame: 6 month

  9. symptom distress(Sleep)

    Pittsburgh Sleep Quality Index

    Time frame: baseline

  10. symptom distress(Sleep)

    Pittsburgh Sleep Quality Index

    Time frame: 1 month

  11. symptom distress(Sleep)

    Pittsburgh Sleep Quality Index

    Time frame: 2 month

  12. symptom distress(Sleep)

    Pittsburgh Sleep Quality Index

    Time frame: 6 month

  13. Cigarette Dependence

    Short-Form Cigarette Dependence Questionnaire

    Time frame: baseline

  14. Cigarette Dependence

    Short-Form Cigarette Dependence Questionnaire

    Time frame: 1 month

  15. Cigarette Dependence

    Short-Form Cigarette Dependence Questionnaire

    Time frame: 2 month

  16. Cigarette Dependence

    Short-Form Cigarette Dependence Questionnaire

    Time frame: 6 month

07

Study locations

1 of 1 sites recruiting
  • Tri-Service Medical Center
    Taipei, Taiwan
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04679636
Lead sponsor
National Defense Medical Center, Taiwan
Responsible party
Yu-Ju Chen (Dean of nursing, National Defense Medical Center, Taiwan) — Principal investigator
First posted
Dec 22, 2020
Start date
Nov 26, 2020
Primary completion
Dec 31, 2023 (estimated)
Completion
Mar 31, 2024 (estimated)
Last update
Mar 23, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion